Chengdu Ruier Pharmaceutical Technology Co., Ltd.

The pharmacokinetic characteristics of bromocriptine mesylate tablets [2.5 mg (calculated as bromocriptine (C32H40BrN5O5))] developed by Chengdu Ruier Pharmaceutical Technology Co., Ltd. and produced by Hangzhou Minsheng Pharmaceutical Co., Ltd. after a single oral administration after meal were studied; bromocriptine mesylate tablets [Parlodel®, 2.5 mg (calculated as bromocriptine (C32H40BrN5O5))] certified by Bridging Pharma GmbH and produced by DOPPEL Farmaceutici S.r.l. were used as the reference preparation. The pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.